HealthNovo says CagriSema delivers greater weight loss than Lilly rival in diabetes trial
Novo Nordisk said its next-generation experimental drug CagriSema produced an estimated average weight loss of 12.4% among diabetes patients in a late-stage trial, surpassing Eli Lilly’s competing treatment.
R
Reuters★★★☆☆2026-09-21 13:45Original
Novo says CagriSema delivers greater weight loss than Lilly rival in diabetes trial
Health